ABSTRACT
OBJECTIVE: Prepregnancy obesity is an epidemic disorder that seriously threatens both maternal and offspring health. This study investigated the effects of ß3-adrenergic receptor (ß3-AR) activation on the perinatal outcomes in a diet-induced prepregnancy obese (PPO) murine model. METHODS: Four-week-old female C57BL/6 mice were fed high-fat diet or chow diet for 16 weeks to yield PPO mice and chow-fed (CF) lean mice, respectively. After successful mating with CF males, the PPO and CF mice were both randomly divided into vehicle control- or CL316,243 (a highly selective ß3-AR agonist)-treated groups. On gestational day 7, subcutaneous infusion of CL316,243 or saline vehicle (1 mg/kg/d) was provided using osmotic pumps. The perinatal outcomes, adipose tissue morphology, and metabolic and inflammatory markers were examined. RESULTS: Chronic ß3-AR agonist infusion induced brown adipose tissue activation and white adipose tissue browning and countered obesity-induced alterations in lipid profiles, insulin resistance, and systemic and local inflammatory states. Moreover, ß3-AR activation was associated with improved placental perfusion and offspring outcomes. CONCLUSIONS: Our results provide proof-of-principle evidence that pharmacological ß3-AR activation may be of therapeutic potential in preventing prepregnancy-obesity-associated adverse maternal and offspring perinatal outcomes.
Subject(s)
Adrenergic beta-2 Receptor Agonists/therapeutic use , Diet, High-Fat/adverse effects , Obesity, Maternal/drug therapy , Adrenergic beta-2 Receptor Agonists/pharmacology , Animals , Disease Models, Animal , Female , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Obese , Pregnancy , Risk Factors , Treatment OutcomeABSTRACT
The aim of this study was to explore the neuritogenic effects of aqueous extracts from the fruiting bodies of Morchella importuna (MEA). 3-(4, 5-dimethythiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was carried out to assess the cytotoxicity of MEA. Neurite outgrowth stimulation assay was used to evaluate the potentiation of neuritogenic activity induced by MEA. The specific inhibitors for TrkA, MEK/ERK and PI3K signaling pathway were served to clarify the mechanism of MEA's neuritogenic effects. It was shown that MEA could mimic neuritogenic activity of NGF, a kind of representative neurotrophic factors with no significant cytotoxicity, and stimulate neurite outgrowth in a dose-dependent manner of PC12 cells. The neuritogenic activity induced by MEA required activity of PI3K/Akt and MEK/ERK1/2 signaling pathways, as well as parts of TrkA receptor. Accordingly, MEA could be used as a promising neuritogenic-stimulation compound for nervous diseases treatment.
